The chief financial officer of Teva Pharmaceutical Industries, Eyal Desheh, is stepping down and will likely be appointed chairman of Isracard, Bank Hapoalim’s credit card company, Israeli news websites reported on Tuesday.
Desheh joined Teva as CFO in 2008 and briefly served as acting CEO from October 2013 to February 2014.
Teva was left without a permanent chief executive in February after Erez Vigodman stepped down, leaving new management to restore confidence in the world’s biggest generic drugmaker after a series of missteps.
A string of costly acquisitions, along with delayed drug launches, have sent Teva shares plummeting and led to calls for management and structural changes, including a possible split into separate generic and branded medicine units.
Officials at Teva declined to comment on the reports.
“Hapoalim is now considering the selection of a new chairman for Isracard,” Israel’s biggest bank said in a statement, noting there were a number of candidates.
“The selection of a chairman will be subject to the recommendation of Bank Hapoalim’s board of directors and the decision of Isracard’s board.”
The appointment would also need approval from the Bank of Israel.
“When a decision is made, we will announce it to the public,” Hapoalim said.
By Tova Cohen
Source: Reuters
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
